David Maris

Elan Risking $2 Billion If Royalty Pharma Walks: Real M&A

Elan Corp. shareholders risk losing $2 billion by listening to the company’s board and rejecting Royalty Pharma’s takeover bid.

Actavis to Buy Warner Chilcott in Women’s Health Effort

Actavis Inc., the largest U.S. maker of generic drugs by market value, agreed to acquire Warner Chilcott Plc for about $5 billion excluding net debt in a deal to expand in women’s health and urology.

Actavis Says It’s in Early Talks to Buy Warner Chilcott

Actavis Inc., the largest U.S. maker of generic drugs by market value, said it’s in “early stage discussions” to buy Warner Chilcott Plc, the drugmaker that unsuccessfully pursued a sale last year.

Icahn May Dust Off Biogen Battle Plan for Forest Labs Fight

Carl Icahn’s effort to shake up drugmaker Forest Laboratories Inc. may look a lot like his three-year fight at Biogen Idec Inc., the world’s biggest maker of multiple sclerosis medicines.

Pfizer Narrows Review of Possible Divestitures to Animal Health, Nutrition

Pfizer Inc., the world’s biggest drugmaker, narrowed its plans to sell or spin off businesses, saying today it would divest only the Animal Health and Baby Food units, with combined annual sales of $5.5 billion.

J&J AIDS Pill Signals $9 Billion in Sales to Ease Recall Woes

Johnson & Johnson , the drugmaker that won approval last week for the first new AIDS medicine since 2008, plans to introduce four drugs this year that may combine for annual sales of $9 billion, helping to offset product recalls and declining profit for medical devices.

Pfizer Names David Simmons to Head Emerging Markets

Pfizer Inc ., seeking to expand its growing international business, named David Simmons head of emerging markets, replacing Jean-Michel Halfon .

Pfizer Said to Have Team Exploring Over-the-Conter Version of Lipitor

Pfizer Inc., the world’s biggest drugmaker, is studying whether its Lipitor cholesterol pill can be sold as an over-the-counter medicine, according to a person familiar with the discussions.

Teva Bets on Stem Cells, Cancer in $6.2 Billion Bid for Cephalon

Teva Pharmaceutical Industries Ltd., swooping in to outbid Valeant Pharmaceuticals International Inc. for Cephalon Inc. , is counting on “high-risk, high-reward” stem-cell treatments and therapies for asthma and lung cancer to help it overcome growing competition to its biggest product.

Pfizer Names 32-Year Veteran Read CEO as Top-Selling Lipitor Faces Rivals

Pfizer Inc. , the world’s biggest drugmaker, named Ian C. Read chief executive officer as the company prepares to face generic competition to its top-selling cholesterol treatment Lipitor.

New York

Brazil

China

Latin America

Airbus A350 Completes First Flight as Wide-Body Battle Heats Up

Donald Leads Mickelson by One Shot as U.S. Open Resumes Play

European Stocks Rise as Stoxx 600 Snaps Four-Day Decline

Iranians Vote for President Who May ‘Make or Break’ Republic

Gold Bears Return as ETP Rout Extends to 17th Week: Commodities